Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90

1.

Inhibition of Senescence-Associated Genes Rb1 and Meis2 in Adult Cardiomyocytes Results in Cell Cycle Reentry and Cardiac Repair Post-Myocardial Infarction.

Alam P, Haile B, Arif M, Pandey R, Rokvic M, Nieman M, Maliken BD, Paul A, Wang YG, Sadayappan S, Ahmed RPH, Kanisicak O.

J Am Heart Assoc. 2019 Aug 6;8(15):e012089. doi: 10.1161/JAHA.119.012089. Epub 2019 Jul 18.

2.

Ablation of the calpain-targeted site in cardiac myosin binding protein-C is cardioprotective during ischemia-reperfusion injury.

Barefield DY, McNamara JW, Lynch TL, Kuster DWD, Govindan S, Haar L, Wang Y, Taylor EN, Lorenz JN, Nieman ML, Zhu G, Luther PK, Varró A, Dobrev D, Ai X, Janssen PML, Kass DA, Jones WK, Gilbert RJ, Sadayappan S.

J Mol Cell Cardiol. 2019 Apr;129:236-246. doi: 10.1016/j.yjmcc.2019.03.006. Epub 2019 Mar 9.

3.

Human antigen R as a therapeutic target in pathological cardiac hypertrophy.

Green LC, Anthony SR, Slone S, Lanzillotta L, Nieman ML, Wu X, Robbins N, Jones SM, Roy S, Owens AP 3rd, Aube J, Xu L, Lorenz JN, Blaxall BC, Rubinstein J, Benoit JB, Tranter M.

JCI Insight. 2019 Feb 21;4(4). pii: 121541. doi: 10.1172/jci.insight.121541. eCollection 2019 Feb 21.

4.

RAPid signaling in platelets.

Nieman MT.

Blood. 2018 Nov 1;132(18):1864-1865. doi: 10.1182/blood-2018-09-872093. No abstract available.

PMID:
30385489
5.

The protease-activated receptor 4 Ala120Thr variant alters platelet responsiveness to low-dose thrombin and protease-activated receptor 4 desensitization, and is blocked by non-competitive P2Y12 inhibition.

Whitley MJ, Henke DM, Ghazi A, Nieman M, Stoller M, Simon LM, Chen E, Vesci J, Holinstat M, McKenzie SE, Shaw CA, Edelstein LC, Bray PF.

J Thromb Haemost. 2018 Dec;16(12):2501-2514. doi: 10.1111/jth.14318. Epub 2018 Nov 22.

PMID:
30347494
6.

Assessment of whole blood coagulation with a microfluidic dielectric sensor.

Maji D, De La Fuente M, Kucukal E, Sekhon UDS, Schmaier AH, Sen Gupta A, Gurkan UA, Nieman MT, Stavrou EX, Mohseni P, Suster MA.

J Thromb Haemost. 2018 Oct;16(10):2050-2056. doi: 10.1111/jth.14244. Epub 2018 Sep 25.

7.

Tranilast Blunts the Hypertrophic and Fibrotic Response to Increased Afterload Independent of Cardiomyocyte Transient Receptor Potential Vanilloid 2 Channels.

Koch SE, Nieman ML, Robbins N, Slone S, Worley M, Green LC, Chen Y, Barlow A, Tranter M, Wang H, Lorenz JN, Rubinstein J.

J Cardiovasc Pharmacol. 2018 Jul;72(1):40-48. doi: 10.1097/FJC.0000000000000588.

8.

Inhibiting Fibronectin Attenuates Fibrosis and Improves Cardiac Function in a Model of Heart Failure.

Valiente-Alandi I, Potter SJ, Salvador AM, Schafer AE, Schips T, Carrillo-Salinas F, Gibson AM, Nieman ML, Perkins C, Sargent MA, Huo J, Lorenz JN, DeFalco T, Molkentin JD, Alcaide P, Blaxall BC.

Circulation. 2018 Sep 18;138(12):1236-1252. doi: 10.1161/CIRCULATIONAHA.118.034609.

9.

Protease activated receptor 4: a backup receptor or a dark horse as a target in antiplatelet therapy?

Han X, Nieman MT.

Ann Transl Med. 2018 Feb;6(3):56. doi: 10.21037/atm.2017.11.36. No abstract available.

10.

Cryo-EM structure of 5-HT3A receptor in its resting conformation.

Basak S, Gicheru Y, Samanta A, Molugu SK, Huang W, Fuente M, Hughes T, Taylor DJ, Nieman MT, Moiseenkova-Bell V, Chakrapani S.

Nat Commun. 2018 Feb 6;9(1):514. doi: 10.1038/s41467-018-02997-4.

11.

Factor XII and uPAR upregulate neutrophil functions to influence wound healing.

Stavrou EX, Fang C, Bane KL, Long AT, Naudin C, Kucukal E, Gandhi A, Brett-Morris A, Mumaw MM, Izadmehr S, Merkulova A, Reynolds CC, Alhalabi O, Nayak L, Yu WM, Qu CK, Meyerson HJ, Dubyak GR, Gurkan UA, Nieman MT, Sen Gupta A, Renné T, Schmaier AH.

J Clin Invest. 2018 Mar 1;128(3):944-959. doi: 10.1172/JCI92880. Epub 2018 Jan 29.

12.

PAR4 (Protease-Activated Receptor 4): PARticularly Important 4 Antiplatelet Therapy.

Han X, Nieman MT.

Arterioscler Thromb Vasc Biol. 2018 Feb;38(2):287-289. doi: 10.1161/ATVBAHA.117.310550. No abstract available.

13.

Optimizing the presentation of bleeding and thrombosis data: Responding to censored data using Kaplan-Meier curves.

Bouck EG, Zunica ER, Nieman MT.

Thromb Res. 2017 Oct;158:154-156. doi: 10.1016/j.thromres.2017.09.011. Epub 2017 Sep 12. No abstract available.

14.

Pharmacological and Activated Fibroblast Targeting of Gβγ-GRK2 After Myocardial Ischemia Attenuates Heart Failure Progression.

Travers JG, Kamal FA, Valiente-Alandi I, Nieman ML, Sargent MA, Lorenz JN, Molkentin JD, Blaxall BC.

J Am Coll Cardiol. 2017 Aug 22;70(8):958-971. doi: 10.1016/j.jacc.2017.06.049.

15.

The non-diuretic hypotensive effects of thiazides are enhanced during volume depletion states.

Alshahrani S, Rapoport RM, Zahedi K, Jiang M, Nieman M, Barone S, Meredith AL, Lorenz JN, Rubinstein J, Soleimani M.

PLoS One. 2017 Jul 18;12(7):e0181376. doi: 10.1371/journal.pone.0181376. eCollection 2017.

16.

Platelet microparticles infiltrating solid tumors transfer miRNAs that suppress tumor growth.

Michael JV, Wurtzel JGT, Mao GF, Rao AK, Kolpakov MA, Sabri A, Hoffman NE, Rajan S, Tomar D, Madesh M, Nieman MT, Yu J, Edelstein LC, Rowley JW, Weyrich AS, Goldfinger LE.

Blood. 2017 Aug 3;130(5):567-580. doi: 10.1182/blood-2016-11-751099. Epub 2017 May 12.

17.

Thrombin-Induced Podocyte Injury Is Protease-Activated Receptor Dependent.

Sharma R, Waller AP, Agrawal S, Wolfgang KJ, Luu H, Shahzad K, Isermann B, Smoyer WE, Nieman MT, Kerlin BA.

J Am Soc Nephrol. 2017 Sep;28(9):2618-2630. doi: 10.1681/ASN.2016070789. Epub 2017 Apr 19.

18.

Transient receptor potential vanilloid 2 function regulates cardiac hypertrophy via stretch-induced activation.

Koch SE, Mann A, Jones S, Robbins N, Alkhattabi A, Worley MC, Gao X, Lasko-Roiniotis VM, Karani R, Fulford L, Jiang M, Nieman M, Lorenz JN, Rubinstein J.

J Hypertens. 2017 Mar;35(3):602-611. doi: 10.1097/HJH.0000000000001213.

PMID:
28009703
19.

Ferric Chloride-induced Murine Thrombosis Models.

Li W, Nieman M, Sen Gupta A.

J Vis Exp. 2016 Sep 5;(115). doi: 10.3791/54479.

20.

Protease-activated Receptor-4 Signaling and Trafficking Is Regulated by the Clathrin Adaptor Protein Complex-2 Independent of β-Arrestins.

Smith TH, Coronel LJ, Li JG, Dores MR, Nieman MT, Trejo J.

J Biol Chem. 2016 Aug 26;291(35):18453-64. doi: 10.1074/jbc.M116.729285. Epub 2016 Jul 11.

21.

Overexpression of miR-223 Tips the Balance of Pro- and Anti-hypertrophic Signaling Cascades toward Physiologic Cardiac Hypertrophy.

Yang L, Li Y, Wang X, Mu X, Qin D, Huang W, Alshahrani S, Nieman M, Peng J, Essandoh K, Peng T, Wang Y, Lorenz J, Soleimani M, Zhao ZQ, Fan GC.

J Biol Chem. 2016 Jul 22;291(30):15700-13. doi: 10.1074/jbc.M116.715805. Epub 2016 May 20.

22.

Protease-activated receptors in hemostasis.

Nieman MT.

Blood. 2016 Jul 14;128(2):169-77. doi: 10.1182/blood-2015-11-636472. Epub 2016 Apr 28. Review.

23.

Dicer1-mediated miRNA processing shapes the mRNA profile and function of murine platelets.

Rowley JW, Chappaz S, Corduan A, Chong MM, Campbell R, Khoury A, Manne BK, Wurtzel JG, Michael JV, Goldfinger LE, Mumaw MM, Nieman MT, Kile BT, Provost P, Weyrich AS.

Blood. 2016 Apr 7;127(14):1743-51. doi: 10.1182/blood-2015-07-661371. Epub 2016 Jan 14.

24.

SERCA2 Haploinsufficiency in a Mouse Model of Darier Disease Causes a Selective Predisposition to Heart Failure.

Prasad V, Lorenz JN, Lasko VM, Nieman ML, Huang W, Wang Y, Wieczorek DW, Shull GE.

Biomed Res Int. 2015;2015:251598. doi: 10.1155/2015/251598. Epub 2015 May 3.

25.

Development and characterization of monoclonal antibodies against Protease Activated Receptor 4 (PAR4).

Mumaw MM, de la Fuente M, Arachiche A, Wahl JK 3rd, Nieman MT.

Thromb Res. 2015 Jun;135(6):1165-71. doi: 10.1016/j.thromres.2015.03.027. Epub 2015 Apr 9.

26.

Disease Severity Correlates with Thrombotic Capacity in Experimental Nephrotic Syndrome.

Kerlin BA, Waller AP, Sharma R, Chanley MA, Nieman MT, Smoyer WE.

J Am Soc Nephrol. 2015 Dec;26(12):3009-19. doi: 10.1681/ASN.2014111097. Epub 2015 Apr 8.

27.

PARtitioning protease signaling.

Nieman MT.

Blood. 2015 Mar 19;125(12):1853-5. doi: 10.1182/blood-2015-01-623835.

PMID:
25792732
28.

Race differences in platelet reactivity: is protease activated receptor 4 a predictor of response to therapy?

Mumaw MM, Nieman MT.

Arterioscler Thromb Vasc Biol. 2014 Dec;34(12):2524-6. doi: 10.1161/ATVBAHA.114.304727. No abstract available.

29.

Common variants in the human platelet PAR4 thrombin receptor alter platelet function and differ by race.

Edelstein LC, Simon LM, Lindsay CR, Kong X, Teruel-Montoya R, Tourdot BE, Chen ES, Ma L, Coughlin S, Nieman M, Holinstat M, Shaw CA, Bray PF.

Blood. 2014 Nov 27;124(23):3450-8. doi: 10.1182/blood-2014-04-572479. Epub 2014 Oct 7.

30.

Ablation of plasma membrane Ca(2+)-ATPase isoform 4 prevents development of hypertrophy in a model of hypertrophic cardiomyopathy.

Prasad V, Lorenz JN, Lasko VM, Nieman ML, Jiang M, Gao X, Rubinstein J, Wieczorek DF, Shull GE.

J Mol Cell Cardiol. 2014 Dec;77:53-63. doi: 10.1016/j.yjmcc.2014.09.025. Epub 2014 Oct 2.

PMID:
25280781
31.

Acute consumption of a high-fat diet prior to ischemia-reperfusion results in cardioprotection through NF-κB-dependent regulation of autophagic pathways.

Haar L, Ren X, Liu Y, Koch SE, Goines J, Tranter M, Engevik MA, Nieman M, Rubinstein J, Jones WK.

Am J Physiol Heart Circ Physiol. 2014 Dec 15;307(12):H1705-13. doi: 10.1152/ajpheart.00271.2014. Epub 2014 Sep 19.

32.

Targeting the anionic region of human protease-activated receptor 4 inhibits platelet aggregation and thrombosis without interfering with hemostasis.

Mumaw MM, de la Fuente M, Noble DN, Nieman MT.

J Thromb Haemost. 2014 Aug;12(8):1331-41. doi: 10.1111/jth.12619. Epub 2014 Jun 27.

33.

Platelet specific promoters are insufficient to express protease activated receptor 1 (PAR1) transgene in mouse platelets.

Arachiche A, de la Fuente M, Nieman MT.

PLoS One. 2014 May 15;9(5):e97724. doi: 10.1371/journal.pone.0097724. eCollection 2014.

34.

Loss of the AE3 Cl(-)/HCO(-) 3 exchanger in mice affects rate-dependent inotropy and stress-related AKT signaling in heart.

Prasad V, Lorenz JN, Lasko VM, Nieman ML, Al Moamen NJ, Shull GE.

Front Physiol. 2013 Dec 31;4:399. doi: 10.3389/fphys.2013.00399. eCollection 2013.

35.

Protease-activated receptor 1 (PAR1) and PAR4 heterodimers are required for PAR1-enhanced cleavage of PAR4 by α-thrombin.

Arachiche A, Mumaw MM, de la Fuente M, Nieman MT.

J Biol Chem. 2013 Nov 8;288(45):32553-62. doi: 10.1074/jbc.M113.472373. Epub 2013 Oct 4.

36.

Loss of NHE1 activity leads to reduced oxidative stress in heart and mitigates high-fat diet-induced myocardial stress.

Prasad V, Lorenz JN, Miller ML, Vairamani K, Nieman ML, Wang Y, Shull GE.

J Mol Cell Cardiol. 2013 Dec;65:33-42. doi: 10.1016/j.yjmcc.2013.09.013. Epub 2013 Sep 29.

37.

Knockout of the Na,K-ATPase α2-isoform in cardiac myocytes delays pressure overload-induced cardiac dysfunction.

Rindler TN, Lasko VM, Nieman ML, Okada M, Lorenz JN, Lingrel JB.

Am J Physiol Heart Circ Physiol. 2013 Apr 15;304(8):H1147-58. doi: 10.1152/ajpheart.00594.2012. Epub 2013 Feb 22.

38.

Calcium mobilization and protein kinase C activation downstream of protease activated receptor 4 (PAR4) is negatively regulated by PAR3 in mouse platelets.

Arachiche A, de la Fuente M, Nieman MT.

PLoS One. 2013;8(2):e55740. doi: 10.1371/journal.pone.0055740. Epub 2013 Feb 6. Erratum in: PLoS One. 2013;8(12). doi:10.1371/annotation/0956857d-ecf5-4fb7-a834-131915a38a6a.

39.

Angiotensin 1-7 and Mas decrease thrombosis in Bdkrb2-/- mice by increasing NO and prostacyclin to reduce platelet spreading and glycoprotein VI activation.

Fang C, Stavrou E, Schmaier AA, Grobe N, Morris M, Chen A, Nieman MT, Adams GN, LaRusch G, Zhou Y, Bilodeau ML, Mahdi F, Warnock M, Schmaier AH.

Blood. 2013 Apr 11;121(15):3023-32. doi: 10.1182/blood-2012-09-459156. Epub 2013 Feb 5. Erratum in: Blood. 2014 Mar 6;123(10):1622.

40.

Mapping human protease-activated receptor 4 (PAR4) homodimer interface to transmembrane helix 4.

de la Fuente M, Noble DN, Verma S, Nieman MT.

J Biol Chem. 2012 Mar 23;287(13):10414-23. doi: 10.1074/jbc.M112.341438. Epub 2012 Feb 8.

41.

Knockout of the Na,K-ATPase α₂-isoform in the cardiovascular system does not alter basal blood pressure but prevents ACTH-induced hypertension.

Rindler TN, Dostanic I, Lasko VM, Nieman ML, Neumann JC, Lorenz JN, Lingrel JB.

Am J Physiol Heart Circ Physiol. 2011 Oct;301(4):H1396-404. doi: 10.1152/ajpheart.00121.2011. Epub 2011 Aug 19.

42.

Renovascular hypertension using a modified two-kidney, one-clip approach in mice is not dependent on the α1 or α2 Na-K-ATPase ouabain-binding site.

Lorenz JN, Lasko VM, Nieman ML, Damhoff T, Prasad V, Beierwaltes WH, Lingrel JB.

Am J Physiol Renal Physiol. 2011 Sep;301(3):F615-21. doi: 10.1152/ajprenal.00158.2011. Epub 2011 Jun 1.

43.

Murine prolylcarboxypeptidase depletion induces vascular dysfunction with hypertension and faster arterial thrombosis.

Adams GN, LaRusch GA, Stavrou E, Zhou Y, Nieman MT, Jacobs GH, Cui Y, Lu Y, Jain MK, Mahdi F, Shariat-Madar Z, Okada Y, D'Alecy LG, Schmaier AH.

Blood. 2011 Apr 7;117(14):3929-37. doi: 10.1182/blood-2010-11-318527. Epub 2011 Feb 4.

44.

Oral thrombostatin FM19 inhibits prostate cancer.

Nieman MT, LaRusch G, Fang C, Zhou Y, Schmaier AH.

Thromb Haemost. 2010 Nov;104(5):1044-8. doi: 10.1160/TH09-08-0570. Epub 2010 Sep 30.

45.

CLIC5 mutant mice are resistant to diet-induced obesity and exhibit gastric hemorrhaging and increased susceptibility to torpor.

Bradford EM, Miller ML, Prasad V, Nieman ML, Gawenis LR, Berryman M, Lorenz JN, Tso P, Shull GE.

Am J Physiol Regul Integr Comp Physiol. 2010 Jun;298(6):R1531-42. doi: 10.1152/ajpregu.00849.2009. Epub 2010 Mar 31.

46.

AbetaPP/APLP2 family of Kunitz serine proteinase inhibitors regulate cerebral thrombosis.

Xu F, Previti ML, Nieman MT, Davis J, Schmaier AH, Van Nostrand WE.

J Neurosci. 2009 Apr 29;29(17):5666-70. doi: 10.1523/JNEUROSCI.0095-09.2009.

47.
48.

Impaired cardiac contractility in mice lacking both the AE3 Cl-/HCO3- exchanger and the NKCC1 Na+-K+-2Cl- cotransporter: effects on Ca2+ handling and protein phosphatases.

Prasad V, Bodi I, Meyer JW, Wang Y, Ashraf M, Engle SJ, Doetschman T, Sisco K, Nieman ML, Miller ML, Lorenz JN, Shull GE.

J Biol Chem. 2008 Nov 14;283(46):31303-14. doi: 10.1074/jbc.M803706200. Epub 2008 Sep 8.

49.

Thrombostatin FM compounds: direct thrombin inhibitors - mechanism of action in vitro and in vivo.

Nieman MT, Burke F, Warnock M, Zhou Y, Sweigart J, Chen A, Ricketts D, Lucchesi BR, Chen Z, Di Cera E, Hilfinger J, Kim JS, Mosberg HI, Schmaier AH.

J Thromb Haemost. 2008 May;6(5):837-45. doi: 10.1111/j.1538-7836.2008.02937.x. Epub 2008 Feb 25.

50.

Interaction of thrombin with PAR1 and PAR4 at the thrombin cleavage site.

Nieman MT, Schmaier AH.

Biochemistry. 2007 Jul 24;46(29):8603-10. Epub 2007 Jun 27.

Supplemental Content

Loading ...
Support Center